Efficacy and safety of anlotinib in advanced non-small cell lung cancer: a real-world study

K Zhang, X Ma, H Gao, H Wang, H Qin… - Cancer management …, 2020 - Taylor & Francis
Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …
被引用次数：32 相关文章

Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study

K Zhang, X Ma, H Gao, H Wang, H Qin… - Cancer Management …, 2020 - dovepress.com
Purpose: The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …

Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study.

K Zhang, X Ma, H Gao, H Wang, H Qin… - Cancer Management …, 2020 - europepmc.org
Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …
[PDF] semanticscholar.org

[PDF][PDF] Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study

K Zhang, X Ma, H Gao, H Wang… - Cancer …, 2020 - pdfs.semanticscholar.org
Purpose: The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …

Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study

K Zhang, X Ma, H Gao, H Wang… - Cancer …, 2020 - pubmed.ncbi.nlm.nih.gov
Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …

Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study.

K Zhang, X Ma, H Gao, H Wang, H Qin… - Cancer Management …, 2020 - go.gale.com
Purpose: The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …
[HTML] nih.gov

[HTML][HTML] Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study

K Zhang, X Ma, H Gao, H Wang, H Qin… - Cancer Management …, 2020 - ncbi.nlm.nih.gov
Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …